Author: Ravi Shankar

Vancouver, BC, Sept. 23, 2026 (GLOBE NEWSWIRE) — Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) (“Deep Sea Minerals” or the “Company”), a subsea mineral exploration and development company focused on advancing critical mineral opportunities from the deep ocean, is pleased to announce that it has entered into a non-binding and non-exclusive letter of intent (the “LOI”) with Westwin Elements, Inc. (“Westwin”) regarding a proposed joint development agreement to evaluate potential U.S.-based processing routes for polymetallic nodules.

The LOI establishes a framework for the parties to negotiate a definitive joint development agreement in the future, following, among other things, the Company obtaining subsea mineral rights and all licenses, permits and other regulatory approvals required to explore, recover, test mine and harvest subsea polymetallic nodules. Such a joint development agreement would establish a formal framework for the Company and Westwin to jointly evaluate processing and recovery pathways for nickel, cobalt, copper, and manganese contained in polymetallic nodules. Any future joint development, feedstock supply, offtake or commercial processing arrangement would remain subject to further negotiation, applicable conditions and the execution of definitive agreements. There can be no assurance that the Company ever obtains subsea mineral rights or enters into any joint development or other definitive agreement with Westwin.

The LOI, or any future joint development or other definitive agreement with Westwin, is not intended to replace, modify or otherwise affect Westwin’s existing feedstock relationships or arrangements with third parties.

Proposed Joint Technical Evaluation

The LOI contemplates that, under any future joint development agreement with Westwin, the Company would provide representative polymetallic nodule samples and available geological and geochemical data for evaluation and Westwin would undertake bench-and pilot-scale test work to assess potential processing routes. The proposed joint development program would assess the principal processing steps from polymetallic nodule material through intermediate and potential saleable products, with the objective of developing a recommended processing route and process block flowsheet.

Under the LOI, the Company is responsible for the costs associated with providing samples and related data, while Westwin is responsible for the costs of test work conducted at its facilities, unless otherwise agreed by the parties.

The parties contemplate that the proposed technical evaluation would assess whether polymetallic nodules could represent an additional potential feedstock source for future U.S.-based critical mineral processing capacity.

“Evaluating potential downstream processing pathways is an important part of our work to understand how polymetallic nodules could ultimately fit within a U.S.-based critical minerals supply chain,” said James Deckelman, Chief Executive Officer of Deep Sea Minerals Corp. “This non-binding arrangement with Westwin provides a framework for future discussions of a joint development agreement to evaluate the technical work required to assess potential processing routes. The current focus is on technical evaluation, and any future commercial relationship would remain subject to applicable conditions and the negotiation and execution of definitive agreements.”

“Westwin’s potential collaboration with Deep Sea Minerals is an important development towards strengthening the nation’s critical mineral supply chain,” said KaLeigh Long, founder and CEO of Westwin. “By evaluating new potential sources of critical mineral feedstock alongside domestic processing capabilities, we are working to expand the options available to support U.S. national security and resilience. We look forward to bringing Westwin’s processing expertise to this potential collaboration and exploring the potential of polymetallic nodules as an additional domestic resource.”

Potential Future Feedstock Relationship 

If the parties enter into a definitive joint development agreement in the future, and the contemplated technical program identifies a processing route that the parties determine to be technically and commercially viable, the Company and Westwin may consider a longer-term commercial relationship involving the Company supplying Westwin with polymetallic nodule feedstock. Any future supply arrangement would remain subject to, among other things, successful technical evaluation, applicable funding conditions, the Company obtaining the required exploration and/or commercial recovery rights and regulatory approvals, sufficient processing capacity, commercial viability and the negotiation and execution of definitive agreements. The Company has not committed to provide Westwin with any minimum quantity of polymetallic nodule material, and neither party currently has any binding supply, offtake or commercial processing obligation. There can be no assurance that any ongoing commercial relationship with Westwin will ever materialize or that the Company will ever be able to provide a commercial supply of polymetallic nodule feedstock.

Other Corporate Updates

The Company intends to enter into a third extension of its investor relations and marketing agreement with Capital Gain Media Inc. (“CGM”), originally announced on February 24, 2026, and previously extended June 4 and July 9, 2026, subject to the approval of the Canadian Securities Exchange (the “CSE”). Under the proposed extension, CGM would continue to provide investor awareness, digital marketing, content development, and related communication services in support of the Company’s capital markets initiatives. The extension would continue for up to 90 days, or until the allocated marketing budget has been exhausted. The Company intends to allocate an additional marketing budget of US$100,000, plus applicable taxes, for the extended term.

CGM has a business address located at 1111 West Hastings Street, 15th Floor, Vancouver, V6E 2J3 and its principal Graham Colmer can be contacted at admin@capitalgainmedia.com. CGM and its principals are arm’s length from the Company.

ABOUT WESTWIN ELEMENTS, INC.

Westwin Elements is scaling America’s only Class 1 nickel refinery, delivering high-purity Class 1 nickel and specialized nickel products for national security and industrial applications. Using carbonyl refining technology, Westwin is driving critical mineral independence and reshaping the future of sustainable metal refining.
​
For more information, visit www.westwinelements.com.

ABOUT DEEP SEA MINERALS CORP.

Deep Sea Minerals Corp. is a subsea mineral exploration and development company focused on evaluating opportunities to support the future supply of critical minerals through the acquisition, exploration, and development of deep-sea mineral assets.

The Company’s strategy is centered on identifying jurisdictions and geological settings with potential exposure to polymetallic nodule systems, which are recognized for containing combinations of metals that may be relevant to defense, industrial manufacturing, clean energy infrastructure, advanced electronics, and artificial intelligence-related supply chains. These seabed resources represent a largely undeveloped component of the global mineral supply base and are the subject of increasing policy, scientific, and regulatory attention worldwide.

As part of this process, the Company has commenced early-stage engagement with selected governments and regulatory bodies in the Pacific Ocean region to assess potential pathways for future exploration initiatives, subject to applicable international, national, and environmental frameworks.

For further information, please see the Company’s website: https://www.deepseamineralscorp.com

SOCIAL MEDIA

Facebook: https://www.facebook.com/deepseacorp/
Instagram: https://www.instagram.com/deepseacorp
X: https://x.com/deepseacorp
LinkedIn: https://www.linkedin.com/company/deepseacorp
Youtube: https://www.youtube.com/@deepseacorp

ON BEHALF OF THE BOARD
“James A. Deckelman”
James A. Deckelman, Chief Executive Officer

For further information, please contact: 
James A. Deckelman
Chief Executive Officer
Phone: 1-281-467-1279
Email: info@deepseamineralscorp.com

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved the contents of this press release.

Forward-Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively, “forward-looking statements”) that relate to the Company’s current expectations and views of future events. In some cases, these forward-looking statements can be identified by words or phrases such as “may”, “might”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “plan”, “indicate”, “seek”, “believe”, “predict” or “likely”, or the negative or grammatical variations of these terms, or other similar expressions intended to identify forward-looking statements, although not all forward-looking statements include such words. The Company has based these forward-looking statements on its current expectations and projections about future events and financial trends that it believes might affect its financial condition, results of operations, business, prospects and financial needs. Forward-looking statements contained in this news release include, but are not limited to, statements about: the Company’s plans and strategies, including the potential acquisition of subsea mineral exploration or exploitation rights; any future joint development or other definitive agreement with Westwin; the execution of a joint development program; the successful identification of a technically and commercially viable processing route; any supply or other agreement with Westwin; the Company’s ability to supply polymetallic nodule feedstock; and the Company’s third extension of its agreement with CGM.

This forward-looking information and other forward-looking information are based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Material factors underlying forward-looking information and management’s expectations include certain assumptions in respect of, among other things: favourability of operating conditions; the receipt of necessary third party approvals, licences or permits on favourable terms; the result of any potential legal, regulatory or geopolitical conflict resulting from the United States asserting governance of subsea mineral exploration and development in international waters under the Deep Seabed Hard Mineral Resources Act (“DSHMRA”); the continued cooperation and alignment of national interests between the United States and the Cook Islands; the Cook Islands’ intention to grant mining licenses in the future; the availability of equipment; the availability of qualified vessel operators and marine contractors; our ability to obtain financing on acceptable terms; currency exchange and interest rates; the impact of competition; the changes and trends in our industry and the global economy; changes in laws, rules, regulations and global standards; our ability to build our market share; our ability to retain key personnel; transaction opportunities, exploration potential, and precious metals prices; the sufficiency of the Company’s amended application for an exploration licence for a defined area of the Clarion-Clipperton Zone in the Pacific Ocean (the “NOAA Application”) under DSHMRA, submitted on July 17, 2026, in responding to the requests for supplemental information in NOAA’s notice to the Company dated May 26, 2026; that NOAA will require no further information from the Company in order to determine the NOAA Application is in full compliance with applicable regulatory requirements; that the federal-agency consultation, antitrust review, public-comment, certification, environmental-review and hearing processes applicable to the NOAA Application will proceed generally in accordance with the indicative regulatory periods described in the Company’s amended and restated annual information form for the year ended December 31, 2025, dated July 27, 2026 (the “A&R AIF”); that NOAA will not identify material deficiencies relating to the Company’s financial responsibility, technical capability, proposed exploration plan, environmental information, proposed licence area or other regulatory requirements that the Company is unable to address; that a licensing process or invitation will be available under the Cook Islands seabed minerals regime on terms allowing the Company to submit an application for an exploration licence in the exclusive economic zone of the Cook Islands (the “Cook Islands Application”); that the Company will be able to complete the technical, financial, environmental, corporate and work-program materials required for the Cook Islands Application within its anticipated timeframe; that the Company will be able to demonstrate access to sufficient financial resources, technical expertise, vessels, equipment, contractors and environmental capabilities to satisfy the applicable NOAA and Cook Islands regulatory requirements; that the Company will obtain sufficient financing to fund the regulatory, environmental, technical and offshore activities contemplated by its NOAA and Cook Islands work programs when required; that the Cook Islands election process and any related government transition will be completed without material delay; that following the election, the Cook Islands authorities will designate additional parcel blocks or areas for subsea mineral exploration and exploitation; that there will be no material change in Cook Islands policy, legislation, licensing criteria or regulatory priorities following the election; that Westwin will continue to intend to make a joint development or other definitive agreement with the Company in the future; that Westwin will be able to perform the proposed joint development program; the proposed joint development agreement will be executed successfully; the existence of a technically and commercially viable processing route; the Company obtaining all licenses, permits and other regulatory approvals required to explore, recover, test mine and harvest subsea polymetallic nodules; and the existence of a sufficient supply of subsea polymetallic nodules for commercial processing in any area for which the Company may obtain subsea mineral exploration or commercial recovery rights.

The forward-looking information in this news release is necessarily based on a number of opinions, estimates and assumptions that we considered appropriate and reasonable as of the date of the A&R AIF. It is also subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the risk factors and uncertainties described under “Risk Factors” in the A&R AIF, as well as risks related to the highly speculative nature of the Company’s business;  risks related to subsea mineral exploration and development operations; risks related to the Company’s limited business history and no history of earnings; risks related to the availability of future financing and the Company’s ability to continue as a going concern; risks related to the Company’s exploration and development activities on the mineral properties; uncertainties regarding the grade and quality of polymetallic nodules; uncertainties regarding the commercial collection of polymetallic nodules; negative perceptions regarding the collection of polymetallic nodules; pressure and lobbying by non-governmental organizations; uncertainties regarding our future reliance on strategic partnerships; uncertainties regarding technology required for our business; uncertainties regarding the treatment and processing of polymetallic nodules; natural hazards and seasonality; expropriation of potential future operating equipment or assets; technological obsolescence; the Company’s dependence on key personnel; risks related to foreign operations; risks related to acquisitions and integration; changes in laws and regulations; risks related to competition; fluctuations in prices of critical minerals, base and precious metals, other commodities and natural resources; legal and litigation risks; uncertainty and volatility related to stock market prices and conditions; dilution of the interests of shareholders; risks related to geopolitical disputes; risks related to the Company’s officers and directors becoming associated with other natural resource companies, which may give rise to conflicts of interest; risks related to climate change; and risks related to pandemics, epidemics or other health crises. With respect to the specific matters addressed in this news release, additional risks and uncertainties include: the risk that NOAA will not determine the NOAA Application to be in full compliance, will not preserve the Company’s priority of right, or will not issue an exploration licence on acceptable terms or at all; the risk that the Cook Islands Application will not be submitted within the anticipated timeframe, will not be accepted as complete, or will not be approved; the risk that the Cook Islands election process or government transition will be delayed or result in material changes to Cook Islands seabed minerals policy, legislation or licensing criteria; the risk that the Company will be unable to demonstrate sufficient financial resources, technical expertise, vessels, equipment, contractors or environmental capabilities to satisfy applicable regulatory requirements; the risk that the Company will be unable to obtain sufficient financing to fund its planned regulatory, environmental, technical and offshore activities; the risk that the Company’s intended offshore operations will be delayed or prevented by regulatory, operational, environmental, financial or other factors; the risks to which Westwin is exposed; and the risk that Westwin is unable to enter into any definitive agreement with the Company in the future for any reason. If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. The risks, uncertainties, opinions, estimates and assumptions referred to above and described in greater detail under “Risk Factors” in the A&R AIF should be considered carefully by readers.

Although we have attempted to identify important risk factors that could cause actual results or future events to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date of this news release. The forward-looking information contained in this news release represents our expectations as of the date of this news release (or as of the date they are otherwise stated to be made), and is subject to change after such date. We disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable Canadian securities legislation.

DALLAS, Sept. 23, 2026 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that it has formulated and is implementing a comprehensive strategy intended to eliminate both the fraudulent indebtedness asserted by HCLP Nominees, L.L.C. (“HCLP”) and the equity interests in Beneficient and its subsidiaries held by the Company’s former Chief Executive Officer, Brad Heppner, and his affiliated entities (“Heppner Equity Interests”). Through the strategy, the Company also seeks to terminate all other remaining agreements with Heppner or his affiliated entities (“Heppner Agreements”) and have all amounts purportedly owed to them by Beneficient or its subsidiaries under those agreements or otherwise deemed void and unenforceable. The strategy follows Heppner’s May 2026 federal fraud conviction and is a significant component of the Company’s broader effort to transform its balance sheet, simplify its capital structure, and unlock its potential. The Company continues to operate its business and pursue its long-term growth objectives while implementing the strategy.

As previously disclosed, Heppner was convicted on May 7, 2026, of securities fraud, wire fraud and related charges in connection with a fraudulent scheme to enrich himself. The criminal trial revealed overwhelming evidence that Heppner fraudulently concealed his control of HCLP and fabricated the purported HCLP debt. The Company believes the conviction provides substantial support for its position that the purported HCLP debt is invalid and unenforceable. The Company further believes that Heppner’s fraud and other misconduct support substantial claims for damages and other relief, including the elimination of the Heppner Equity Interests and the termination of the Heppner Agreements.

The Company is actively pursuing a consensual resolution with Heppner, with the objective of completing it before his sentencing, currently scheduled for October 21, 2026. The proposed resolution is designed to achieve a complete separation from Heppner, assist him in making restitution to other victims of his criminal conduct, and would include:

• the elimination of the contested HCLP debt, including approximately $130 million of principal and accrued interest;
• the conversion and exchange of all the Heppner Equity Interests, including preferred equity of a Company subsidiary with an aggregate liquidation preference of approximately $850 million, into an aggregate of 162,132 shares of the Company’s Class A common stock;
• the termination or voiding of all remaining contractual arrangements involving Heppner or his affiliated entities and the extinguishment, without payment, of all amounts purportedly owed under those arrangements or otherwise, totaling approximately $88 million.

If completed, the resolution would eliminate substantially all of the Company’s debt; end Heppner’s ownership of the Company’s Class B common stock and his associated super-voting, board-appointment, and consent rights; and resolve the substantial dilution overhang associated with his preferred equity interests. As part of the consensual resolution, the Company would provide customary releases to Heppner and his affiliated entities.

If an acceptable resolution cannot be reached with Heppner, the Company is prepared to swiftly and decisively pursue all available claims and remedies against Heppner, HCLP, and other Heppner-affiliated entities and individuals who received proceeds derived from his fraudulent conduct.

The Company has cooperated fully and transparently with the government’s investigation and prosecution of Heppner and will continue to cooperate, including in connection with the forfeiture or disposition of his or his entities’ assets and efforts to provide restitution to victims.

“Since the conviction, we have focused on pursuing a resolution that fully addresses Mr. Heppner’s misconduct and the harm it caused Beneficient,” said James G. Silk, Chief Executive Officer. “Our objective is a complete separation through the elimination of the purported HCLP debt and all of Mr. Heppner’s remaining equity, contractual and governance interests in the Company. We believe that outcome is both just and necessary to protect Beneficient from further harm. Achieving it would transform our balance sheet, unlock substantial value for our stockholders, and position the Company and its operations to realize its full potential.”

The Company has not entered into a definitive agreement with respect to the proposed resolution, and there can be no assurance that a consensual resolution will be reached or, if litigation becomes necessary, that the Company will achieve its objectives. The Company continues to dispute the validity, enforceability, ownership, amount and value of the purported HCLP debt and all other claims and interests asserted by Heppner or his affiliated entities and will disclose material developments as appropriate.

About Beneficient
Beneficient (Nasdaq: BENF) – Ben, for short – is on a mission to democratize the global alternative asset investment market by providing traditionally underserved investors − mid-to-high net worth individuals, small-to-midsized institutions and General Partners seeking exit options, anchor commitments and preferred liquidity services for their funds − with solutions that could help them unlock the value in their alternative assets.

Its subsidiary, Beneficient Fiduciary Financial, L.L.C., received its charter under the State of Kansas’ Technology-Enabled Fiduciary Financial Institution (TEFFI) Act and is subject to regulatory oversight by the Office of the State Bank Commissioner.

For more information, visit www.trustben.com or follow us on LinkedIn.

Contacts
Matt Kreps: 214-597-8200, mkreps@darrowir.com
Michael Wetherington: 214-284-1199, mwetherington@darrowir.com
Investor Relations: investors@beneficient.com

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company’s strategy and objectives concerning the HCLP debt and other Heppner-related interests; the Company’s ability to obtain a judgment or other binding resolution declaring the purported HCLP debt and related liens void, invalid or unenforceable; the potential conversion and exchange of Heppner-related equity interests; and the anticipated effects of these efforts on the Company’s liabilities, collateral, capital structure, financial flexibility, legacy matters and stockholders. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on management’s current expectations, beliefs, assumptions and information and are not guarantees of future performance or results.

Important factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include, among others, the outcome and timing of litigation, negotiations and other proceedings involving Heppner, HCLP and related parties; the ability to enter into a definitive agreement with respect to a proposed resolution; the outcome of any appeal or other proceeding relating to Mr. Heppner’s conviction; the risk that the Company is unable to obtain the relief it seeks or otherwise implement its strategy; disputes concerning the validity, enforceability, ownership, amount, value or conversion of the HCLP claims or other Heppner-related interests; the need for third-party or governmental actions, consents or approvals; the accounting and tax treatment of any resolution; the costs and diversion of management’s attention and resources associated with these matters; and the other risks, uncertainties and factors set forth under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release and the Company’s filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. The Company assumes no obligation to update or revise forward-looking statements to reflect actual results, subsequent events or circumstances, except as required by applicable law.

Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-up

SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that updated clinical data will be delivered in an oral presentation at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026), taking place September 29th – October 2nd at the Cité Internationale Universitaire de Paris:

Abstract Title:	AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy, Combined with Rituximab Generates Robust Efficacy Responses in 11 Patients with Sjögren Disease
Presenting Author:	Guillermo J. Valenzuela, M.D., F.A.C.R. Medical Director, Integral Rheumatology & Immunology Specialists
Session:	Breaking news from clinical trials
Date/Time/Location:	Thursday, October 1, 2026 at 4:30 – 6:00 pm CEST, Amphitheater Adenauer

For more information on this and other abstracts, please visit the ISSjD 2026 abstract book.

About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva is initiating a Phase 3 registrational trial of its lead program, AlloNK^® (also known as AB-101), in refractory rheumatoid arthritis (RA) in the second half of 2026. AlloNK is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity for a range of antibodies, including anti-CD20 antibodies, and drive deep B-cell depletion. Initial clinical data evaluating AlloNK in combination with anti-CD20 antibodies have demonstrated encouraging activity across multiple B-cell-driven autoimmune diseases, together with a tolerability profile supportive of outpatient administration. Artiva is developing AlloNK to drive deep B-cell depletion through a scalable, outpatient-administered treatment regimen compatible with community rheumatology settings. In addition to refractory RA, AlloNK is being evaluated in Sjögren disease, systemic sclerosis and myositis.

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the potential benefits, accessibility, practicality, effectiveness, safety and tolerability of AlloNK, including based on interim pooled data across clinical trials, and the potential for administration in an outpatient community setting; the registrational Phase 3 trial for AlloNK, including trial design, expectations for response rates, and timing of initiation, future updates on site activation and enrollment, and topline data readout; and Artiva’s ability to generate sufficient data to support a BLA submission; clinical data expected to be available and presented in refractory RA, SjD and SSc, and the timing of such data disclosures; the number of patients with data from the basket study who would be expected to meet the key eligibility criteria for the planned Phase 3 trial; Artiva’s ability to realize the potential benefits associated with FDA RMAT designation for AlloNK; Artiva’s beliefs regarding its competitive position, including its belief that AlloNK may be the first deep or deep B-cell depleting therapy of any modality to reach patients with, and be approved and commercialized in, refractory RA; and Artiva’s future results of operations and financial position, including cash runway. These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available to Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties, including, without limitation, risks and delays relating to initiation of the Phase 3 registrational trial, activation of clinical trial sites, patient enrollment and the availability and timing of disclosure of data; risks that future clinical trial results may not be consistent with interim, initial, preliminary, or topline results or results from prior preclinical studies or clinical trials, or with Artiva’s expectations; the risk that the number of patients, or the duration of follow-up for such patients, available for presentation differs from current expectations; the risk that differences exist between trial designs, patient characteristics and other factors for the Phase 3 trial, Artiva-sponsored Phase 2a basket trial and investigator-initiated basket trial, and caution should be exercised in drawing any conclusions from such data across separate trials as such pooling and comparative data is inherently limited and such data may not be directly comparable; the risk that other deep B-cell depleting therapies may advance more rapidly than Artiva currently anticipates, that Artiva’s assessment of publicly disclosed competitor development timelines may be incomplete or inaccurate, and that Artiva may not achieve or be the first to achieve regulatory approval or commercialization of a therapy in this category; the risk that Artiva’s registrational strategy is based in part on recent interactions with the FDA and later feedback from the FDA may be inconsistent with past interactions; Artiva’s ability to obtain adequate financing to fund its planned clinical trials and other expenses; risks inherent in developing product candidates; and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause Artiva’s actual results to differ from current expectations are discussed in Artiva’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in Artiva’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors & Media
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com

Source: Artiva Biotherapeutics, Inc.

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to announce that it has entered into an option agreement (the “Option Agreement”) with McKnight Resources AB (“McKnight”), an arm’s length party, pursuant to which McKnight has granted to Brixton the sole, exclusive and irrevocable right and option (the “Option”) to acquire an undivided 100% interest in and to certain mineral exploration permits located in Hällefors Municipality, Örebro County, south central Sweden, commonly known by the names “Silvergruvan 100” and “Silvergruvan 200” (collectively, the “Silvergruvan Property”). The Option Agreement remains subject to the receipt of acceptance from the TSX Venture Exchange (the “TSXV”). No finder’s fees are payable in connection with the Option.

The Silvergruvan Property comprises 1,460 hectares and is prospective for silver, gold, lead, zinc, antimony and indium. The Silvergruvan Property saw historical mining activity spanning from the 1600s to the late 20^th century and sits on the western margin of the Bergslagen province, placing the property in immediate proximity to major active polymetallic operations. Silvergruvan shares similar geology to major silver-lead-zinc deposits like Garpenburg⁽¹⁾, Sala, and Zinkgruvan⁽¹⁾ in the region.

Chairman and CEO Gary R. Thompson, stated: “The Silvergruvan Property represents an attractive opportunity for new discoveries in a region that has not seen much modern exploration, yet it shares similar geology to Garpenburg, one of the world’s most productive underground zinc mines. In 2025, Boliden stated most of this mine’s revenue was from silver and is a long-life mine with deep rooted mineralization where mining reaches 1,500 meters depth and remains open.” ^(1,2)

According to Boliden, in 2025, the most valuable commodity for Garpenberg was silver. Silver accounted for 47% of the revenue, followed by zinc 32%, gold at 11%, lead at 10% and copper at less than 1%.⁽²⁾

Silvergruvan History

1635 – silver first discovered.⁽³⁾

Tumi Resources (news release, May 15, 2008) stated, ” No production figures are available for the eastern silver mines, but during 1878-1896 and 1915-1917, 9,000 tonnes were produced from the western silver mines grading approximately 1,560 g/t Ag, 12% Zn and 38% Pb. Records indicate that between 1639 and 1852, Hällefors produced just over 480,000 oz of silver…”.

1892 – From the report, “The Minerals of the Silver Mines of Hällefors”, the average grade of ore from the western fields was 0.156% Ag. In the years of 1639 – 1852, the silver-bearing ore mined was 15 tons.⁽⁴⁾

1977 – Boliden restarts underground mining at eastern fields.

1997 – Boliden forms JV with Lundin Group and drills 2,000 meters at western fields.

2008 – Tumi Resources forms JV with Goldsearch; conducts EM survey, no drilling.

2026 – McKnight acquired Silvergruvan through staking.

2026 – Rock grab samples collected by McKnight with assays in Figure 1 (below).

Figure 1. Select rock grab sample photographs/assays from the Silvergruvan Property 2026.

Sixteen waste dump rock grab samples from the Silvergruvan Project were collected by McKnight and of these; 9 samples were greater than 200 g/t silver including 6 were greater than 500 g/t silver with a high of 800 g/t silver; 5 samples returned greater than 1 g/t gold with a high of 1.8 g/t gold; 8 samples returned greater than 5% lead with a high of 18.4% lead; 8 samples returned greater than 5% zinc with a high of 20.90% zinc; 5 samples returned greater than 1000 ppm antimony with a high of 1480 ppm antimony; and 4 samples returned greater than 100 ppm indium with a high of 188 ppm indium.

Infrastructure and Logistics

The Silvergruvan Property location has year-round heavy vehicle road access, excellent proximity to the national industrial power grid, and an experienced local mining workforce.

Current Mineral Resources

No mineral resource statement has been calculated at the Silvergruvan Property in modern times.

Transaction Highlights

Brixton may exercise the Option on completion of the following:

Date	Share Issuances(*)		Exploration Expenditures
On or before the 1st anniversary of the Option effective date	$150,000		$300,000
On or before the 2nd anniversary of the Option effective date	$250,000		$1,000,000
On or before the 3rd anniversary of the Option effective date	$500,000		$2,000,000
Any time following completion of the above Share issuances and exploration expenditures	$600,000
TOTAL	$1,500,000		$3,300,000

(*) Any common shares in the capital of the Company (the “Shares”) issued pursuant to the Option Agreement shall have an issue price, as and when issued, equal to the 20-day volume weighted average trading price of the Shares on a recognized stock exchange in Canada on which the Shares are then listed, such price being based on the 20 trading days preceding the date the Company elects to issue such Shares; provided, however, that the issue price shall not be less than $0.50 being the ‘Discounted Market Price’ of Shares on the TSXV as of the date of this news release.

Upon Brixton exercising the Option, it shall grant a 2.0% net smelter returns royalty (the “Royalty”) on the Silvergruvan Property in favour of McKnight, subject to a right at any time to reduce the Royalty to 1.0% by paying $1,500,000 or issuing Shares equal to $1,500,000, such Shares shall have an issue price, as and when issued, equal to the 20-day volume weighted average trading price of the Shares on a recognized stock exchange in Canada on which the Shares are then listed, such price being based on the 20 trading days preceding the date the Company elects to issue such Shares; provided, however, that the issue price shall not be less than $0.50 being the ‘Discounted Market Price’ of Shares on the TSXV as of the date of this news release.

All Share issuances and exploration expenditures are at the discretion of Brixton. Brixton may make up any shortfall in exploration expenditures for a period by making a cash payment to McKnight before the end of such period. Brixton may also accelerate the Option by making any Share issuances and exploration expenditures within a shorter period of time. Brixton shall act as operator during the Option period.

All Shares issued pursuant to the Option Agreement and Royalty will be subject to a hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws. In addition, each tranche of Share issuance under the Option Agreement will be subject to a voluntary lock-up subject to a release schedule of 25% on issuance, 25% four months from the date of issuance, 25% eight months from the date of issuance and 25% twelve months from the date of issuance.

Reference Sources and Links
⁽¹⁾ https://www.boliden.com/operations/mines/boliden-garpenberg/
⁽¹⁾ https://www.boliden.com/operations/mines/boliden-zinkgruvan/
⁽²⁾ Mineral Resources and Mineral Reserves Garpenberg 2025-12-31 (click link)
⁽³⁾ History of Mines in Sweden (click link)
⁽⁴⁾ Nils Sundius, Alexander Parwel and Benita Rajandi, Geological Survey of Sweden: “The Minerals of the Silver Mines of Hällefors”, 1966.

Qualified Person (QP)

Mr. Gary Thompson, P.Geo., is the Chairman and CEO and a senior geologist for the Company who is a ‘Qualified Person’ as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Thompson has reviewed and approved the technical information presented herein. The QP conducted a site visit on August 25, 2026 and considers Silvergruvan a property of merit and recommends further exploration. Further, the QP has not completed sufficient work on the historical data to confirm the accuracy of the information provided, and there is no certainty that further exploration will result in a mineral resource.

About Brixton Metals Corporation

Brixton is a Canadian exploration company focused on the advancement of its mining projects. Brixton wholly owns four exploration projects: Brixton’s flagship Thorn copper-gold-silver-molybdenum project, the Langis and Hudson Bay silver projects in Ontario, the Hog Heaven copper silver-gold project in NW Montana, USA, which is optioned to Ivanhoe Electric Inc., and the Atlin Goldfields project located in northwest BC, which is optioned to Eldorado Gold Corporation. Brixton Metals Corporation shares trade on the TSX-V under the ticker symbol BBB, and on the OTCQX under the ticker symbol BBBXF. For more information about Brixton, please visit our website at www.brixtonmetals.com.

On Behalf of the Board of Directors

Mr. Gary R. Thompson, Chairman and CEO
info@brixtonmetals.com

For Investor Relations inquiries, please contact: Mr. Michael Rapsch, Vice President Investor Relations. email: michael.rapsch@brixtonmetals.com or call Tel: 604-630-9707.

Follow us on:
LinkedIn | Twitter/X | Facebook | Instagram

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Information set forth in this news release may involve forward-looking information under applicable securities laws. Forward-looking information are statements and information that relate to future, not past, events. In this context, forward-looking information often addresses expected future business and financial performance, and often contains words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”; information and statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All information other than information of historical fact included herein are forward-looking information, including, without limitation, information regarding the Company’s business plans and strategies of operations, the Silvergruvan Property and potential for exploration; the Option and TSXV approval of the Option Agreement. By its nature, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in the annual information form of the Company or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward-looking information is based on management’s beliefs, estimates and opinions on the date that such information is provided and the Company undertakes no obligation to update forward-looking information if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking information.

Link:
https://brixtonmetals.com/wp-content/uploads/2026/09/NR_Figure-1_23Sept2026-scaled.png

Evaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of MitoCareX’s future in-vitro drug discovery programs

Ness Ziona, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) — Nexentis Technologies Inc. , (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that its wholly-owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), a drug discovery company, is evaluating additional approaches for obtaining proteins used in its in-vitro research activities.

MitoCareX is evaluating established, commercially available approaches for obtaining proteins as part of its disciplined effort to broaden the research tools available for its in-vitro activities. The assessment will examine whether these approaches are suitable for MitoCareX’s research requirements and may support greater flexibility as its discovery programs progress.

By assessing additional established approaches for obtaining proteins for controlled in-vitro studies, MitoCareX seeks to broaden its research capabilities while also maintaining flexibility in the advancement of its discovery programs. The evaluation remains at an early stage, and there can be no assurance that any approach under consideration will be adopted or provide the anticipated benefits.

“Evaluating appropriate approaches to obtain proteins is part of our methodical approach to developing reliable in-vitro research capabilities,” said Dr. Alon Silberman, Chief Executive Officer of MitoCareX Bio. “Our goal is to assess tools and methods that may support the quality and consistency of our research while maintaining the flexibility required as our discovery programs progress.”

About MitoCareX Bio Ltd.
MitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc., is advancing a focused drug-discovery platform designed to translate multidisciplinary scientific capabilities into potential therapeutic candidates. By integrating biology, chemistry and computationally enabled research, MitoCareX supports ongoing research activities directed toward candidate identification and development within its drug-discovery efforts. https://mitocarexbio.com/

About Nexentis Technologies Inc.
Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd, a drug discovery company. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

For additional details, please visit https://nexentistech.com/

Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses MitoCareX’s evaluation of additional approaches for obtaining proteins, whether any such approaches are suitable for its research requirements, whether any approach under consideration will be adopted, and the potential of such approaches to enhance access to research materials, increase research flexibility, and support the advancement of MitoCareX’s future in-vitro drug discovery programs. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com

SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities, previously announced on September 22, 2026. The termination results from an assessment by the Company’s management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company’s stockholders. No securities were sold in connection with the proposed offering.

The offering was made by Biomea pursuant to a shelf registration statement on Form S-3 (File No. 333-289262) that was filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 5, 2025 and declared effective by the SEC on August 15, 2025, and a preliminary prospectus supplement that was filed with the SEC on September 22, 2026.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Biomea’s beliefs and expectations regarding the termination of its previously-announced public offering, and uncertainties related to market conditions. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Biomea’s most recent annual report on Form 10-K filed on March 24, 2026 and subsequent quarterly reports on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Biomea’s other filings with the SEC. Any forward-looking statements contained in this press release represent Biomea’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Biomea explicitly disclaims any obligation to update any forward-looking statements, except as required by law.

Contact:

Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com

Pilots across North America, Continental Europe and the UK & Ireland set foundation for rollout in 2027

GREENWICH, Conn., Sept. 23, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced global pilots of a new Labor Management System (LMS) designed to enhance workforce planning capabilities and operating efficiencies.

The pilots, being conducted at sites across the U.S., UK, Netherlands, Poland and Spain, represent an important step toward the creation of a standard single global labor management solution that can be deployed consistently across GXO’s operations worldwide.

“We are continuously looking for new ways to help our sites operate more efficiently while delivering even greater value to our customers,” said Bart Beeks, Chief Operations Officer, GXO. “A single global labor management system is a key lever of The GXO Way, our global operations framework for standardizing and scaling operational excellence. A standardized LMS will support more informed decision-making and help us drive productivity at scale. The pilots are an important milestone in building a consistent, data-driven approach to labor management across our operations worldwide.”

The LMS provides real-time visibility into labor performance and workforce planning, helping site leaders better align resources with customer demand while improving operational efficiency. By providing a common platform and standardized performance framework, the LMS will help accelerate operational improvements while supporting GXO’s growth and profitability objectives.

GXO expects to begin scaling the LMS platform across its network in 2027, as part of its broader strategy to standardize best practices, accelerate continuous improvement and strengthen operational excellence across its global footprint.

About GXO

GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and is positioned to capitalize on the rapid growth of ecommerce, automation and outsourcing. GXO has over 150,000 team members across more than 1,000 facilities, totaling more than 200 million square feet. The company serves the world’s leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut. Visit GXO.com for more information and connect with GXO on LinkedIn, X, Facebook, Instagram and YouTube.

Media contacts
Matthew Schmidt 
+1 203-307-2809 
matt.schmidt@gxo.com

Kathleen Juviler
+1 203-921-9121
Kathleen.juviler@gxo.com

GREAT NECK, N.Y., Sept. 23, 2026 (GLOBE NEWSWIRE) —

Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) announced today that, in accordance with the board approved dividend declared on July 28, 2026, a cash dividend of $0.11 per share will be paid to all shareholders of record on October 8, 2026. The dividend will be paid on October 15, 2026.

Contact:
Assaf Ran, CEO
(516) 444-3400
www.linkedin.com/in/assafran
SOURCE: Manhattan Bridge Capital, Inc.

WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vienna, Austria from September 30-October 3, 2026.

EADV Congress 2026 Presentation Details:

Late-Breaker Oral Presentation:

Title: Efficacy and Safety of Abdakibart (ABD), a Humanized High Affinity and Potency IgG4 Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa at Week 16; IHS4 Subgroup and Lesion Type ANdT Results of the Phase 2 Placebo Controlled LOTUS Trial
Presenter: Dr. Martina Porter, Assistant Professor of Dermatology at Harvard Medical School and Vice Chair for Research and Academics, Department of Dermatology at Beth Israel Deaconess Medical Center
Location: Hall A
Date: Thursday, October 1, 2026 5:00pm CEST

Poster Presentation:

Title: Efficacy and Safety of Abdakibart, a Selective Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa; Primary Results of the Placebo-Controlled Phase 2 LOTUS Trial
Location: ePoster Area; Inflammatory Skin Diseases – Part II
Date: Wednesday, September 30, 2026 7:00am CEST

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Media Response:
Media@lexeotx.com

Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com